Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Google Secures Pentagon AI Deal for Classified Projects 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
DENVER, April 17, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its first quarter 2017 financial results on Thursday, May 4, 2017, before the opening of the U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | Thursday, May 4, 2017 | |
| Time | 9:00 a.m. EDT | |
| Toll free (U.S.) | (888) 372-9592 | |
| Webcast (live and replay) | www.bioscrip.com | |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 8579499.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts: Jeffrey M. Kreger Chief Financial Officer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
